CVS and UnitedHealth lost ground on Medicare ratings. Who gained?

Humana surged as much as 16.5% after its flagship Medicare Advantage contract improved to four stars from 3.5, lifting the share of members in plans rated four stars or higher to 95% for 2027 from 20% in 2026. Evercore ISI estimates the ratings could generate $4.8 billion in bonus payments in 2028, but medical costs remain elevated: Humana’s benefit ratio rose to 91.2% in Q2, and it plans to exit plans affecting about 600,000 members in 2027. Consensus EPS is $9.14 for 2026, down 47%, before projected recovery to $17.31 in 2027; analysts’ estimates remain divided.

Analysis

The ratings change improves HUM’s earnings bridge, but the key question is whether quality bonuses translate into durable margin recovery rather than being absorbed by elevated utilization, GLP-1 costs, and repricing. The 2028 benefit is conditional on maintaining ratings; prior rating volatility makes it less bankable than a recurring operating improvement. Meanwhile, exiting plans may reduce low-return exposure but creates near-term membership and revenue attrition, and could send some seniors to competitors without guaranteeing those plans earn attractive margins.

The immediate repricing likely captures much of the ratings surprise. Over 1–3 months, HUM’s quarterly benefit ratio and management’s 2027 enrollment/pricing commentary matter more than the headline bonus estimate. Over 6–18 months, execution on cost control and stability of Star Ratings determine whether the earnings rebound is credible. CVS and UNH face potential relative pressure if more members are outside four-star plans, but their broader businesses mean the effect should not be extrapolated directly to consolidated earnings. BlackRock’s clinic JV is a modest capital-access positive, not a material standalone thesis.

Contrarian risk: investors may anchor on forecast 2027–28 EPS while treating the 2026 earnings trough and ratings reversibility as temporary. The thesis weakens if medical costs remain elevated despite exits and repricing, or if future ratings erode. No reliable price-based stop or valuation conclusion is possible from the supplied data.

Key Decisions for Investors

• Do not chase the post-announcement gap. Consider a staged HUM long only after the price consolidates and the next results show the benefit ratio stabilizing; define risk around the earnings thesis, not an invented price level.
• Treat the projected bonus and EPS rebound as conditional: monitor benefit ratio, 2027 membership retention/pricing, and subsequent Star Ratings. Exit or reduce if cost trends worsen despite plan exits or management lowers its recovery outlook.
• Keep CVS and UNH on relative-risk watch rather than shorting mechanically. Reassess only when company disclosures quantify the share of members affected and the resulting revenue or earnings sensitivity; lower-rated membership alone does not establish a consolidated earnings hit.